Last reviewed · How we verify
NCT05880667
Adaptive Radiation for Abdominopelvic Metastases
Phase 1 trial testing Adaptive Stereotactic Body Radiation in Neoplasm - Soft Tissue Pelvis Malignant Secondary in 30 participants. Currently enrolling.
1 June 2028
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 August 2023 |
| Primary completion | 1 June 2028 |
| Estimated completion | 1 June 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Adaptive Stereotactic Body Radiation
Conditions studied
- Neoplasm - Soft Tissue Pelvis Malignant Secondary — all drugs for Neoplasm - Soft Tissue Pelvis Malignant Secondary →
- Malignant Neoplasm of Stomach — all drugs for Malignant Neoplasm of Stomach →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
18 and older, any sex, with Neoplasm - Soft Tissue Pelvis Malignant Secondary or Malignant Neoplasm of Stomach. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CT-Guided Adaptive Radiotherapy for the Treatment of Technically Challenging Oligometastatic Disease: A Case Report.
Lee PL, Chen X, ElDib A, Galloway TJ, et al · · 2024 · PMID 39493113 · DOI 10.7759/cureus.70765
Verify or expand the search:
- PubMed search for NCT05880667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05880667 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05880667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing